Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 5018 results found since Jan 2013.

Sequencing Therapy for Elderly Chronic Lymphocytic Leukemia Patients in the Era of Novel Therapies: An Overview of Randomized Clinical Trials
Conclusion:The rapid clinical development of novel therapy agents has changed the prognosis for CLL patients. Ibrutinib is considered as a standard option and an up front therapy for high risk CLL patients especially who are elderly and have del 17p, despite its significant toxicity profile in very elderly patients (80 years and above) where multiple deaths were reported. Future prospects include ibrutinib combinations with frontline chemo-immunotherapy (CIT) and other novel agents for TN and RR del 17p negative patients.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ahmad, M. Q., Sohail, C. S., Yasir, M., Tariq, M. J., Akbar, A., Khalil, M. J., Usman, M., Fraz, M. A., Jahngir, M. U., Khan, A. Y., Ijaz, A., Durer, C., Durer, S., Anwer, F. Tags: 642. CLL: Therapy, excluding Transplantation Source Type: research

The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis
Conclusions The important information provided by present meta-analysis is that the improvement over traditional treatments observed with BCR or BCL2 pathway inhibitors is common to all patients with R/R CLL, including those patients with unfavorable and favourable prognostic parameters. BCR signal transduction and BCL2 inhibitors have broad utility and overcome many but not all of the traditional poor risk molecular features in CLL.Figure 1.DisclosuresMolica: Gilead: Other: Advisory board; AbbVie: Other: Advisory board; Roche: Other: Advisory board; Jansen: Other: Advisory board. Levato: Novartis: Other: Advisory board. S...
Source: Blood - November 21, 2018 Category: Hematology Authors: Molica, S., Giannarelli, D., Mirabelli, R., Levato, L., Shanafelt, T. D. Tags: 642. CLL: Therapy, excluding Transplantation Source Type: research

Outcomes of Unrelated Bone Marrow Transplantation in Patients with Thalassemia
Conclusions. This study showed that unrelated donor BMT can successfully cure a proportion of patients with thalassemia. Remarkably, despite 57% of patients were in class 3 of risk the 5-year OS and TFS rates were 90%. We conclude that class 3 patients with thalassemia who have a suitably matched unrelated donor should not be denied the option of transplantation.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Gaziev, J., Isgro, A., Paciaroni, K., Marziali, M., De Angelis, G., Ribersani, M., Alfieri, C., Andreani, M. Tags: 732. Clinical Allogeneic Transplantation: Results Source Type: research

A Systematic Literature Review to Assess Long-Term Outcomes Associated with Splenectomy in Patients with Chronic Immune Thrombocytopenia
Conclusions: Although more than 100 studies reported long-term outcomes for patients with cITP treated with splenectomy, available evidence on the durability of response and long term safety are limited. In general, most measures of efficacy declined over time, while complications (infections, bleeding, VTE) and mortality increased over time. The extent to which the outcomes for splenectomy differ from currently available treatments is unclear. Additional data are needed to understand the long-term benefits and risks of splenectomy in patients with cITP.DisclosuresNellesen: Analysis Group, Inc.: Employment; Novartis Pharma...
Source: Blood - November 21, 2018 Category: Hematology Authors: Nellesen, D., Said, Q., Shak, N., Patton, C., Lucas, S., Graves, J. A., Nezami, B., Cuker, A. Tags: 903. Outcomes Research-Non-Malignant Hematology Source Type: research

Autoimmune hemolytic anemia.
Authors: Hill A, Hill QA Abstract The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise approach that aims to identify laboratory and clinical evidence of hemolysis and then determine the immune nature of hemolysis with the direct anti-globulin test. Once alternative causes for these findings have been excluded, AIHA is established, and the clinician must search for secondary causes, as well as identify the type of AIHA. Rituximab is now the preferred second-line treatment for primary warm AIHA and first-line treatment for primary cold agglutinin disease (CAD), either as monotherapy or com...
Source: Hematology ASH Education Program - December 7, 2018 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer.
Abstract PROBLEM IDENTIFICATION: Subcutaneous (SC) formulations for monoclonal antibodies (mAbs) must be evaluated for efficacy and safety in comparison with preexisting IV formulations to identify potential benefits and risks. LITERATURE SEARCH: This is a systematic review of clinical trials. MEDLINE®/PubMed, EMBASE, Cochrane Library, LILACS (Latin American and Caribbean Health Sciences Literature), and reference lists were searched for relevant studies. DATA EVALUATION: Data regarding efficacy and safety were registered in a form designed for this review. Risk of bias was assessed using the Jadad scal...
Source: Oncology Nursing Forum - December 15, 2018 Category: Nursing Authors: Rodrigues Ferreira A, Farias Azevedo E Tags: Oncol Nurs Forum Source Type: research

New molecular pathological strategies for malignant iris tumors.
CONCLUSION: Molecular pathological analyses will become essential in the future management of iris tumors because they play a key role towards a personalized treatment approach. PMID: 30623224 [PubMed - as supplied by publisher]
Source: Der Ophthalmologe - January 8, 2019 Category: Opthalmology Authors: Kakkassery V, Jünemann AM, Scheef BO, Grisanti S, Heindl LM Tags: Ophthalmologe Source Type: research

Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.
Conclusions: IVGC, alone or combination with OR, and teprotumumab should be preferred as the most effective strategies for active moderate to severe TED. Teprotumumab showed profound effect on proptosis reduction. OIGC, OR, and somatostatin analogs showed some statistical benefit and can be employed as second-line treatment strategies. RTX is a promising biologic agent, but more RCTs are required to define its appropriate role in treating TED. PMID: 30647961 [PubMed]
Source: Journal of Ophthalmology - January 18, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma.
We present a rare case of spontaneous remission of a diffuse large B-cell lymphoma of the central nervous system as well as its subsequent reappearance in another location. The atypical presentation misled the neurosurgeons and neurologists, delaying diagnosis and treatment. The patient underwent brain biopsy after the relapse and started radiotherapy and chemotherapy with cytarabine + methotrexate + rituximab. As of 32 months after the diagnosis, the patient remained asymptomatic, with no focal neurological deficits and the disease in complete remission. A PubMed search of the literature up to June 2017 regarding spontane...
Source: Acta Medica Portuguesa - January 27, 2019 Category: General Medicine Tags: Acta Med Port Source Type: research

Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature
We present a case of a young male with refractory PAN and ongoing biopsy evidence of active vasculitis despite optimal standard therapies, who was successfully treated with interleukin-6 antagonist, tocilizumab. A 24-year-old male presented with severe immobilizing polyneuropathy and myalgias. Clinical features included fasciitis, tenosynovitis, early signs of polyneuropathy, and panniculitis, which were largely refractory to the standard therapies. The previous unsuccessful treatments included high-dose glucocorticoids, methotrexate, cyclophosphamide, rituximab, anakinra, and intravenous immunoglobulins. Magnetic resonanc...
Source: Rheumatology International - February 1, 2019 Category: Rheumatology Source Type: research

The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review
ConclusionNon-TNF-targeted biologics have been associated with favorable effects on endothelial dysfunction as already demonstrated for TNF inhibitors. Future studies are needed to ascertain the impact of this mediations on arterial stiffness in RA patients.
Source: Autoimmunity Reviews - March 5, 2019 Category: Allergy & Immunology Source Type: research

No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
CONCLUSION: HCL and HCLv are uncommon lymphoid neoplasms that lead to a characteristic constellation of symptoms. The emergence of PAs and novel targeted agents have improved the likelihood and durability of responses for these patients. PMID: 30841702 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - March 5, 2019 Category: Drugs & Pharmacology Authors: King AC, Kabel CC, Pappacena JJ, Stump SE, Daley RJ Tags: Ann Pharmacother Source Type: research

The Treatment of Chronic Lymphatic Leukemia.
CONCLUSION: Recent progress in the development of novel treatment options gives hope that CLL may soon be a controllable disease. Even at present, chemoimmuno- therapy can achieve a progression-free survival of more than eight years in certain genetically defined subgroups of CLL patients. PMID: 30855005 [PubMed - in process]
Source: Deutsches Arzteblatt International - March 12, 2019 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Therapy of pemphigus.
CONCLUSION: Therapy of pemphigus has been greatly improved by the employment of rituximab. The use of glucocorticosteroids, associated with a high number of adverse events and elevated mortality, could be reduced by the additional use of rituximab. After approval of rituximab for the treatment of pemphigus by the US Food and Drug Administration in 2018, licensing in Europe is expected in 2019. PMID: 30887081 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - March 20, 2019 Category: Dermatology Tags: Hautarzt Source Type: research

Efficacy and Safety of Rituximab in Vasculitic Nneuropathy: A Systematic Review of the Literature
ConclusionsRituximab seems an effective and safe treatment for VN in the context of cryoglobulinemic vasculitis. Evidence for specific efficacy in VN in the context of other types of vasculitis is lacking.ResumenObjetivoRevisar la eficacia y seguridad del rituximab en neuropatía vasculítica (NV).MétodosSe realizó una búsqueda en la literatura de Medline y Embase hasta 2017. Los términos incluidos guardaron relación con «vasculitis», «neuropatía vasculítica» y «rituximab». Dicha búsqueda fue realizada por 2 revisores. El resultado principal fue la eficacia del rituximab.ResultadosTras seleccionar inicialment...
Source: Reumatologia Clinica - April 6, 2019 Category: Rheumatology Source Type: research